Rekvina Laboratories Ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 526075
₹48.89
Sept. 30, 2026 · BSE · bse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #149 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Rekvina Laboratories Ltd (this stock) 54 — 20.8% 986.4% — 22 — 51

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹56 Cr
EV / EBITDA
Data unavailable.
EV / Sales
28.84x
Market cap / Sales
28.09x
Earnings yield
Data unavailable.

Quarterly Financials

↑ Positive
Quarterly Net Profit

Jun 2026 quarterly net profit is Rs -0 Cr, up 245.7% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 1 -0 -0 ₹-0.2000
March 31, 2026 1 -0 -0 ₹-0.1000
Dec. 31, 2025 0 -0 -0 ₹-0.2100
Sept. 30, 2025 0 -0 -0 ₹0.0600
June 30, 2025 — -0 -0 ₹0.0000
March 31, 2025 — -0 -0 ₹-0.0700
Dec. 31, 2024 — -0 -0 ₹0.0400
Sept. 30, 2024 — -0 -0 ₹0.1100
June 30, 2024 — -0 -0 ₹-0.0040
March 31, 2024 — -0 -0 ₹
Dec. 31, 2023 — -0 -0 ₹
Sept. 30, 2023 — -0 -0 ₹-0.0200
March 31, 2023 0 -0 -0 ₹-0.0010

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23
Total income (before exceptional items)————————————0
Operating revenue1100————————0
Other income————————————0
Operating expenses110000———————
Operating profit-0-0-0-0—————————
Operating profit margin-17.9%-8.3%-35.8%-17.9%—————————
Depreciation000000———————
Interest000000——————0
Exceptional items, gain / (loss)—————————————
Profit before tax-0-0-0-0-0-0-0-0-0-0-0-0-0
Tax—————————————
Net profit-0-0-0-0-0-0-0-0-0-0-0-0-0
EPS-0.20-0.10-0.210.060.00-0.070.040.110.00——-0.020.00
Net profit (TTM)-0-0-0-0-0-0-0-0-0-0-0-0-0
EPS (TTM)-0.45-0.25-0.220.030.080.08———————

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 23Mar 21Mar 19Mar 18Mar 17
Total income (before exceptional items) — — ———————
Operating revenue — — ———————
Other income — — ———————
Operating expenses — — 2†——————
Operating profit — — ———————
Operating profit margin — — ———————
Depreciation — — 0†——————
Interest — — 0†——————
Exceptional items, gain / (loss) — — 0†0†0†0†0†0†0†
Profit before tax — — -0†-0†-0†-0†-0†-0†-0†
Tax — — ———————
Net profit — — -0†-0†-0†-0†-0†-0†-0†
EPS — — -0.25†0.08†—————

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 23Mar 21Mar 19Mar 18Mar 17
Operating margin———————
EBIT margin———————
PBT margin———————
Net margin———————
Interest coverage———————
Dividend payout———————
Earnings retention———————
Current ratio0.49x3.89x—————
Quick ratio0.49x3.89x—————
Debt to equity———————
Return on equity———————
Return on assets-21.4%†-469.2%†—————
Return on capital employed———————
Asset turnover———————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 -1 0 1 0 -1
March 31, 2025 -0 0 0 0 -0

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 1 -1 -4 1 0 1 2 0 0 0
March 31, 2025 0 -0 -3 0 0 0 0 0 0 0

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.